Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trials.

NPJ breast cancer·2026
Same author

New Perspectives in the Management of Triple-Negative Breast Cancer.

Breast care (Basel, Switzerland)·2025
Same author

Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole.

Breast cancer research and treatment·2025
Same author

Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer.

Oncoimmunology·2023
Same author

Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update.

Wiener klinische Wochenschrift·2022

Related Experiment Video

Updated: May 11, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Competing risks in low-risk breast cancer.

Kathrin Strasser-Weippl1, Paul E Goss

  • 1From the Harvard Medical School and Avon Breast Cancer Center of Excellence, Massachusetts General Hospital Cancer Center, Boston, MA; Center for Oncology, Hematology and Palliative Care, Vienna, Austria.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 30, 2013
PubMed
Summary

Identifying low-risk breast cancer requires integrating tumor and patient factors. Quantifying treatment benefits for these patients necessitates advanced decision models incorporating gene signatures and side effect risks.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Related Experiment Videos

Last Updated: May 11, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Area of Science:

  • Oncology
  • Genomics
  • Biostatistics

Background:

  • Advances in breast cancer research allow for the identification of tumors with a very low risk of recurrence.
  • Prognostic markers, including clinicopathologic features and gene signatures, aid in predicting distant spread in low-risk breast cancer cohorts.
  • Defining "low-risk" breast cancer necessitates considering patient-specific factors like comorbidities and age alongside tumor characteristics.

Purpose of the Study:

  • To emphasize the importance of a comprehensive definition of "low-risk" breast cancer.
  • To highlight the need for accurate quantification of treatment benefits in low-risk disease.
  • To advocate for the development of sophisticated decision models for treatment recommendations.

Main Methods:

  • Review of current data on prognostic features and gene signatures in breast cancer.
  • Analysis of patient-related factors influencing mortality risk.
  • Discussion of challenges in quantifying treatment benefits and comparing them to side effect risks.

Main Results:

  • Current definitions of low-risk breast cancer are evolving with the integration of gene signatures.
  • Patient-related factors significantly impact the perceived risk of mortality, potentially outweighing cancer recurrence risk.
  • Quantifying treatment benefits in low-risk scenarios is complex due to variability and individual side effect risks.

Conclusions:

  • Accurate identification of low-risk breast cancer requires a holistic approach combining tumor biology and patient health status.
  • Effective treatment decision-making for low-risk breast cancer patients depends on reliable quantification of treatment efficacy and toxicity.
  • Future clinical decision support tools must integrate gene signature data and patient-specific information to guide treatment recommendations.